Preliminary evidence of reduced cognitive inhibition in methamphetamine-dependent individuals

Salo, Ruth; Nordahl, Thomas E.; Possin, Kate; Leamon, Martin H.; Gibson, David R.; Galloway, Gantt P.; Flynn, Neil; Henik, Avishai; Pfefferbaum, Adolf; Sullivan, Edith V.

doi:10.1016/s0165-1781(02)00111-7

Cited by 170 publications

(144 citation statements)

References 41 publications

Supporting

Mentioning

126

Contrasting

Unclassified

Order By: Relevance

“…These results suggest that methamphetamine-addicted individuals, like healthy human volunteers (Johnson et al, 2000), experience measurable increases in cognitive performance with experimentally administered intravenous methamphetamine. This is the case despite the expectation of deteriorated cognitive functioning (Salo et al, 2002) due to presumed fronto-striatal damage (Ernst et al, 2000;Volkow et al, 2001). Replication of these results would not only establish this human laboratory paradigm for testing cognitive performance and attention among methamphetamine-dependent individuals but also provide added support for the notion that addicted individuals might continue taking the drug to maintain or enhance cognitive performance.…”

Section: Introductionmentioning

confidence: 75%

Effects of topiramate on methamphetamine-induced changes in attentional and perceptual-motor skills of cognition in recently abstinent methamphetamine-dependent individuals

Johnson

Roache

Ait-Daoud

et al. 2007

Progress in Neuro-Psychopharmacology and Biological Psychiatry

View full text Add to dashboard Cite

Methamphetamine-dependent individuals often cite the need to maintain enhanced cognitive performance and attention as a reason for continuing or relapsing to drug-taking. Further, methamphetamine addicts might not comply with taking a potentially therapeutic medication if it had a profound effect on these cognitive processes. Topiramate, a sulfamate-substituted fructopyranose derivative, has been suggested as a putative therapeutic medication for treating methamphetamine dependence. Examination of topiramate's effects on cognitive performance and attention is a clinically and scientifically important component of understanding its potential therapeutic profile. In 10 male and female individuals who met DSM-IV criteria for methamphetamine dependence, we examined the effects of low (50 mg b.i.d.)-and high (100 mg b.i.d.)-dose topiramate -in both the presence and absence of low (15 mg)-and high (30 mg)-dose intravenous methamphetamine -on cognitive performance, attention, and concentration on the rapid visual information processing task and the digit symbol substitution test. Intravenous methamphetamine enhanced cognitive performance, attention, and concentration among recently withdrawn methamphetamine addicts -an effect that hitherto had not been well characterized. Topiramate's cognitive effects were mixed and rather paradoxical, with a tendency to improve attention and concentration both alone and in the presence of methamphetamine while worsening psychomotor retardation. No deleterious interaction occurred between topiramate and methamphetamine on any of these cognitive processes. While clinical studies with topiramate should Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. NIH Public Access

show abstract

Section: Introductionmentioning

confidence: 75%

Effects of topiramate on methamphetamine-induced changes in attentional and perceptual-motor skills of cognition in recently abstinent methamphetamine-dependent individuals

Johnson

Roache

Ait-Daoud

et al. 2007

Progress in Neuro-Psychopharmacology and Biological Psychiatry

View full text Add to dashboard Cite

show abstract

“…Clinically, mAMPH users have impairments in motor skills (Volkow et al, 2001;Wang et al, 2004), maintaining attention (Nordahl et al, 2003;Salo et al, 2002), decision-making skills (Rogers et al, 1999;Paulus et al, 2002), and set-shifting abilities Ornstein et al, 2000). One particularly prominent feature noted in several studies with human mAMPH users is that of these users' poor recall and recognition memory (Ornstein et al, 2000;Volkow et al, 2001;Simon et al, 2002;Gonzalez et al, 2004).…”

Section: Discussionmentioning

confidence: 99%

Methamphetamine Influences on Recognition Memory: Comparison of Escalating and Single-Day Dosing Regimens

Belcher

Feinstein

O’Dell

et al. 2007

Neuropsychopharmacol

View full text Add to dashboard Cite

Methamphetamine (mAMPH) is an addictive drug that produces memory and recall impairments in humans. Animals subjected to a binge mAMPH dosing regimen that damages brain dopamine and serotonin terminals show impairments in an object recognition (OR) task. Earlier research demonstrated that preceding a single-day mAMPH binge regimen with several days of increasing mAMPH doses greatly attenuates its neurotoxicity in rats. The escalating dose (ED) paradigm appears to mimic the human pattern of escalating drug intake. The current aim was to test whether an ED plus binge mAMPH regimen produces OR impairments. In addition to its translational value, this experiment helps address whether monoaminergic neurotoxicity accounts for OR impairments seen after mAMPH administration. To further address this issue, a separate experiment investigated both OR impairments and monoamine transporter integrity in groups of rats treated with a range of mAMPH doses during a single day. An ED mAMPH regimen attenuated the acute hyperthermic response to the subsequent mAMPH binge and prevented the OR impairments and reductions in [125 I]RTI-55 binding to monoamine transporters in striatum, hippocampus (HC), and perirhinal cortex (pRh) that otherwise occur 1 week after the mAMPH binge. Single-day mAMPH regimens (4 Â 1 mg/kg to 4 Â 4 mg/kg, s.c.) dose-dependently produced acute hyperthermia and, 1 week postmAMPH, produced dose-dependent impairments in OR and reductions in monoamine transporter binding. The OR impairments of single-day mAMPH-treated rats correlated with monoaminergic transporter loss in ventral caudate-putamen, HC, and pRh. In aggregate, these findings suggest a correspondence between mAMPH-induced monoaminergic injury and the resulting OR deficits.

show abstract

“…A total of 10 regions of interest (ROIs) were selected because of prior demonstrations of functional abnormalities associated with MA abuse: parietal cortex (Brodmann areas (BAs) 1,2,3,5,7,19,39,40), thalamus, dorsal striatum, ventral striatum, medial orbitofrontal cortex (gyrus rectus and medial orbital gyrus; BA 11), lateral orbitofrontal cortex (lateral, posterior orbital and inferior frontal gyri; BAs 47, 11), infragenual ACC (BAs 25, 32), supragenual ACC (BAs 24, 32, 33), insula (BA 13) and amygdala. 1,6,8,9 ROIs were drawn on the structural MR template provided in SPM2, using MEDx Software (Sensor Systems, Sterling, VA, USA).…”

Section: Discussionmentioning

confidence: 99%

“…[1][2][3][4][5] These deficits appear to reflect regional cerebral dysfunction. When abstinent for 1 week, MA abusers studied with [F-18]fluorodeoxyglucose (FDG) and positron emission tomography (PET) have more severe self-reports of depressive symptoms than control subjects, and these self-reports covary with relative uptake of the radiotracer in anterior cingulate cortex (ACC) and amygdala.…”

Section: Introductionmentioning

confidence: 99%

Changes in cerebral glucose metabolism during early abstinence from chronic methamphetamine abuse

et al. 2007

View full text Add to dashboard Cite

Changes in brain function during the initial weeks of abstinence from chronic methamphetamine abuse may substantially affect clinical outcome, but are not well understood. We used positron emission tomography with [F-18]fluorodeoxyglucose (FDG) to quantify regional cerebral glucose metabolism, an index of brain function, during performance of a vigilance task. A total of 10 methamphetamine-dependent subjects were tested after 5-9 days of abstinence, and after 4 additional weeks of supervised abstinence. A total of 12 healthy control subjects were tested at corresponding times. Global glucose metabolism increased between tests (P = 0.01), more in methamphetamine-dependent (10.9%, P = 0.02) than control subjects (1.9%, NS). Glucose metabolism did not change in subcortical regions of methamphetaminedependent subjects, but increased in neocortex, with maximal increase ( > 20%) in parietal regions. Changes in reaction time and self-reports of negative affect varied more in methamphetamine-dependent than in control subjects, and correlated both with the increase in parietal glucose metabolism, and decrease in relative activity (after scaling to the global mean) in some regions. A robust relationship between change in self-reports of depressive symptoms and relative activity in the ventral striatum may have great relevance to treatment success because of the role of this region in drug abuse-related behaviors. Shifts in corticalsubcortical metabolic balance either reflect new processes that occur during early abstinence, or the unmasking of effects of chronic methamphetamine abuse that are obscured by suppression of cortical glucose metabolism that continues for at least 5-9 days after cessation of methamphetamine self-administration.

show abstract

Preliminary evidence of reduced cognitive inhibition in methamphetamine-dependent individuals

Cited by 170 publications

References 41 publications

Effects of topiramate on methamphetamine-induced changes in attentional and perceptual-motor skills of cognition in recently abstinent methamphetamine-dependent individuals

Effects of topiramate on methamphetamine-induced changes in attentional and perceptual-motor skills of cognition in recently abstinent methamphetamine-dependent individuals

Methamphetamine Influences on Recognition Memory: Comparison of Escalating and Single-Day Dosing Regimens

Changes in cerebral glucose metabolism during early abstinence from chronic methamphetamine abuse

Contact Info

Product

Resources

About